Video description on GLP-1 weight-loss drugs: fat loss, muscle, and weight regain after stopping

https://www.dralexnewsletter.com/ Join the community by signing up to my daily newsletter! Practical health advice, straight to your inbox, every morning. What actually happens to your body, and your muscle, when a weight loss injection like Ozempic, Wegovy or Mounjaro is doing all the heavy lifting? These GLP1 medications can deliver remarkable fat loss and real protection for your heart, yet the weight often creeps back once the injections stop, and that tells us a lot about what they can and can't fix. In this video I look at semaglutide and tirzepatide alongside insulin resistance, visceral fat, muscle loss and long term metabolic health. Over the last few years these drugs have moved from diabetes clinics into everyday conversation, helped along by celebrity weight loss stories and a worrying online market in unlicensed vials. I go through how they work in the gut and brain, what the big trials found, and why using a serious prescription medicine as a cosmetic shortcut changes the balance of risk, including pancreatitis and gallbladder problems. I also talk about why weight goes on in the first place, from poor sleep and chronic stress to ultra processed food, menopause and certain medications, and why your body pushes back so hard after weight loss. The idea I keep coming back to is using the treatment as a window, a chance to build up your protein, fibre, strength training and daily habits so you keep the benefits whatever you and your doctor decide next. I also cover who may genuinely need to stay on treatment for the long haul, and the questions worth asking before you start. In this video you'll learn: -How Ozempic, Wegovy and Mounjaro work on your gut, pancreas and appetite -What the big semaglutide and tirzepatide trials showed for weight loss and heart health -Why celebrity culture and online vials made these drugs riskier -The difference between losing weight and getting metabolically healthy -The hidden drivers of weight gain that an injection can't touch -How to protect your muscle with protein, fibre and resistance training -What happens to your weight and blood sugar when treatment stops -Who may benefit from staying on treatment long term -The questions to ask your doctor before you start Whether you're already on a weight loss injection, thinking about asking your GP, or just trying to make sense of the hype, this is a practical look at how to come out the other side stronger, healthier and in better shape for the years ahead. TIMESTAMPS 00:00 – Introduction 01:45 – What these injections are actually doing inside you 03:20 – The celebrity problem 05:09 – Losing weight and getting healthy are two different jobs 06:46 – The reasons the weight went on, which the drug can't touch 08:22 – So what does the stepping stone actually mean 11:07 – The people who should stay on it, and there's no shame in it 12:03 – So how do you decide whether this is the right thing for you 13:48 – Closing REFERENCES Once-Weekly Semaglutide in Adults with Overweight or Obesity https://pubmed.ncbi.nlm.nih.gov/33567185/ Tirzepatide Once Weekly for the Treatment of Obesity https://pubmed.ncbi.nlm.nih.gov/35658024/ Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://pubmed.ncbi.nlm.nih.gov/37952131/ Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension https://pubmed.ncbi.nlm.nih.gov/35441470/ Long-term persistence of hormonal adaptations to weight loss https://pubmed.ncbi.nlm.nih.gov/22029981/ Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite https://pubmed.ncbi.nlm.nih.gov/15583226/ Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake https://pubmed.ncbi.nlm.nih.gov/31105044/ Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss https://pubmed.ncbi.nlm.nih.gov/37796527/ Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials https://pubmed.ncbi.nlm.nih.gov/35344001/ Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33755728/ Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined https://pubmed.ncbi.nlm.nih.gov/33951361/ Disclaimer: This is not personal medical advice and does not override what your doctor says. #dralex #doctoralex #ozempic #weightloss #glp1 #mounjaro